Inhibrx
INBX
135 hedge funds and large institutions have $855M invested in Inhibrx in 2026 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 54 increasing their positions, 35 reducing their positions, and 26 closing their positions.
2,097% more call options, than puts
Call options by funds: $24.8M | Put options by funds: $1.13M
54% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 35
0.96% less ownership
Funds ownership: 88% → 87.04% (-0.96%)
4% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 26
2% less funds holding
Funds holding: 138 → 135 (-3)
15% less capital invested
Capital invested by funds: $1.01B → $855M (-$156M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$18.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$13M |
| 3 |
CLGM
Capitolis Liquid Global Markets
New York
|
+$9.27M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$7.86M |
| 5 |
Morgan Stanley
New York
|
+$7.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CP
Caligan Partners
New York
|
-$25.6M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$14.8M |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$7.27M |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$6.92M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$6.6M |
INBX Hedge Fund Activity: Q1 2026 in Review
135 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Inhibrx (INBX) for Q1 2026, worth a combined $855M — down 15% from $1.01B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of INBX and 25 opened new positions — a net loss of 1 holder — while 35 trimmed existing stakes and 54 added.
The largest buyer was Woodline Partners, adding an estimated $18.2M. The largest seller was Caligan Partners, exiting entirely with an estimated $25.6M sold.
- 135 institutional investors held Inhibrx (INBX) as of Q1 2026, down from 138 in Q4 2025.
- Funds reported $855M of Inhibrx stock for Q1 2026, down 15% quarter-over-quarter.
- 25 funds opened new Inhibrx positions in Q1 2026 and 26 closed out, a net change of -1 holder.
- The largest Inhibrx buyer in Q1 2026 was Woodline Partners, an estimated $18.2M added.
- The largest Inhibrx seller in Q1 2026 was Caligan Partners, an estimated $25.6M sold.
Based on aggregated 13F filings for Q1 2026.